Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

David Wallace

Executive Editor

Birmingham, UK

Having previously worked in the European chemicals industry, Dave has been with Generics Bulletin since 2010. Keeping a close eye on deals, corporate strategy and market developments in the off-patent sector, he also brings his background and education in law to bear on industry litigation as well as national legislative and regulatory affairs, with a particular interest in France where he has lived and studied in the past. A regular delegate to generics and biosimilars events and conferences as well as a frequent panel moderator, he maintains close links with industry representatives around the world. He also organizes and judges the annual Global Generics & Biosimilars Awards. In his spare time, he enjoys art and playing the piano.

Latest From David Wallace

Entering The GGB Awards: One Week To Go!

An additional week has been added to the deadline for companies to submit their entries for the Global Generics & Biosimilars Awards 2024, ahead of our ceremony in Milan on 9 October.

Generic Drugs Biosimilars

Re-Elected Von Der Leyen Sets Out EU Commission Plans For Critical Medicines Act

As she was re-elected as president of the European Commission, Ursula von der Leyen set out plans for the next European Commission that include a Critical Medicines Act to secure the supply chain.

Europe Supply Chain

After Humira Biosimilars, Will It Be Groundhog Day For Stelara?

With ustekinumab biosimilars set to launch in Europe imminently and in the US early next year, the off-patent industry may be wondering whether it will be in for a rerun of its experiences with competition on Humira – or whether the landscape has changed sufficiently to allow for different pricing and uptake trends. 

Biosimilars Generic Drugs

Biosimilars Report Bolsters IGBA’s Calls To Streamline Development Process

The IGBA has renewed calls to streamline biosimilar development by reducing comparative clinical studies and using the same comparator product across international jurisdictions, citing the findings of a recent publication by the International Pharmaceutical Regulators Programme’s Biosimilars Working Group.

Biosimilars Clinical Trials

Generics Bulletin Explains: After Humira Biosimilars, Will It Be Groundhog Day For Stelara?

With ustekinumab biosimilars set to launch in Europe imminently and in the US early next year, the off-patent industry may be wondering whether it will be in for a rerun of its experiences with competition on Humira – or whether the landscape has changed sufficiently to allow for different pricing and uptake trends. Generics Bulletin looks at the expectations of a host of industry leaders.

Biosimilars Launches

UK Prices Continue To Shoot Up In June

The latest UK generic pricing information from WaveData shows multiple products doubling or even trebling their average prices in June.

Market Intelligence Pricing Strategies
See All
UsernamePublicRestriction

Register